Clincosm LogoSign in Get a demo

antineoplastic agents

Showing 1 - 25 of 28
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)

Recruiting
  • Neoplasms
  • +12 more
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Oct 28, 2023

Tumors, Carcinoma, Squamous, Antineoplastic Agents Trial (Nivolumab Injection [Opdivo])

Not yet recruiting
  • Neoplasms
  • +2 more
  • Nivolumab Injection [Opdivo]
  • (no location specified)
Jul 19, 2023

Hormone Receptor Positive Breast Carcinoma, Breast Tumors, Tumors, Breast Trial in Italy (Liquid biopsy and CT scan)

Recruiting
  • Hormone Receptor Positive Breast Carcinoma
  • +6 more
  • Liquid biopsy and CT scan
  • Bergame, Bergamo, Italy
  • +6 more
Apr 13, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

Prostatic Tumors, Tumor Metastasis, Urogenital Tumors Trial in Worldwide (Abemaciclib, Abiraterone, Prednisone or Prednisolone)

Recruiting
  • Prostatic Neoplasms
  • +16 more
  • Birmingham, Alabama
  • +296 more
Jan 18, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

Recruiting
  • Non-Small Cell Lung Cancer
  • +13 more
  • furmonertinib 240 mg
  • +2 more
  • Yuma, Arizona
  • +37 more
Dec 14, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

Active, not recruiting
  • Multiple Myeloma
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +8 more
May 24, 2022

NSCLC, Antineoplastic Agents Trial in Edmonton (Experimental intervention)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Antineoplastic Agents
  • Experimental intervention
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
May 23, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Advanced Solid Tumours, Actinium-225, Antineoplastic Agents Trial in Australia, Canada, United States ([111In]-FPI-1547

Recruiting
  • Advanced Solid Tumours
  • +4 more
  • [111In]-FPI-1547 Injection
  • +3 more
  • Duarte, California
  • +12 more
Mar 2, 2022

Carcinoma, Carcinoma, Hepatocellular, Liver Tumors Trial in Guangzhou (Hepatic arterial infusion chemo, Folfox Protocol,

Not yet recruiting
  • Carcinoma
  • +8 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Lei Zhang
Sep 22, 2021

Urothelial Carcinoma, Anlotinib, Urogenital Tumors Trial in Tianjin (Anlotinib, Cisplatin, Carboplatin)

Not yet recruiting
  • Urothelial Carcinoma
  • +6 more
  • Tianjin, China
    Tianjin Medical Unversity Second Hospital
Aug 30, 2021

Urinary Bladder Tumors, Urologic Tumors, Urogenital Tumors Trial in Shanghai (tislelizumab and BCG)

Recruiting
  • Urinary Bladder Neoplasms
  • +5 more
  • tislelizumab and BCG
  • Shanghai, Shanghai, China
    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Jun 10, 2021

Ovarian Tumors, Fallopian Tube Tumors, Tumors by Site Trial (Drug: Anlotinib, Drug: Carboplatin/Paclitaxel)

Not yet recruiting
  • Ovarian Neoplasms
  • +14 more
  • Drug: Anlotinib
  • Drug: Carboplatin/Paclitaxel
  • (no location specified)
Mar 17, 2021

Ovarian Tumors, Fallopian Tube Tumors, Endocrine Gland Tumors Trial in Nanjing (Niraparib, Bevacizumab)

Unknown status
  • Ovarian Neoplasms
  • +23 more
  • Nanjing, Jiangsu, China
    JiangSu Cancer Hospital
Nov 8, 2020

Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Tumors, Tumors by Site Trial in Nanjing (Anlotinib, Olaparib)

Recruiting
  • Ovarian Cancer
  • +18 more
  • Nanjing, Jangsu, China
    JiangSu Cancer Hospital
Oct 29, 2020

Hepatocellular Carcinoma, Liver Tumors, Digestive System Tumors Trial in Chengdu (TACE combined with sorafenib and PD-1 mAb)

Recruiting
  • Hepatocellular Carcinoma
  • +7 more
  • TACE combined with sorafenib and PD-1 mAb
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Sep 14, 2020

Breast Tumor, Antineoplastic Agents, Anlotinib Trial in Beijing (Anlotinib Hydrochloride)

Completed
  • Breast Neoplasm
  • +2 more
  • Anlotinib Hydrochloride
  • Beijing, Beijing, China
    National Cacner Center/ Cancer Hospital,Chinese Academy of Medic
Jul 27, 2020

Antineoplastic Agents Trial in Roma (Cetuximab, FOLFIRI)

Completed
  • Antineoplastic Agents
  • Roma, Italy
    Fondazione Policlinico Universitario A. Gemelli IRCCS
Mar 29, 2020

Coronary Artery Disease, Antineoplastic Agents Trial in China (study group, control group)

Active, not recruiting
  • Coronary Artery Disease
  • Antineoplastic Agents
  • study group
  • control group
  • Beijing, Beijing, China
  • +24 more
Nov 19, 2019

Testicular Tumors, Tumors, Germ Cell and Embryonal, Tumors Trial in Bratislava (Avelumab)

Completed
  • Testicular Neoplasms
  • +6 more
  • Bratislava, Slovakia
    National Cancer Institute
Mar 3, 2019

Breast Tumor, Antineoplastic Agents, Antiemetics Trial in Mexico City (Palonosetron, Ondansetron)

Unknown status
  • Breast Neoplasm
  • +3 more
  • Mexico City, Mexico
    Instituto Nacional de Cancerología
Jul 27, 2018

Prostatic Tumor, Genital Tumors, Male, Tumors, Abdominal Trial in Germany (STI571 (Glivec®))

Completed
  • Prostatic Neoplasm
  • +7 more
  • STI571 (Glivec®)
  • Aachen, Germany
  • +12 more
May 31, 2017